Herpes simplex virus type -1 ( HSV -1 ) has been demonstrated as a potentially useful gene delivery vector for gene therapy due to its high efficiency of in vivo transduction. The helper virus -dependent, HSV -1 amplicon vectors were developed for easier operation and their larger capacity. In this study, the herpes simplex virus type -1 thymidine kinase ( HSVtk ) gene was cloned into the pHE700 amplicon vector to make an HE7tk vector and used for in vivo gene delivery. Human melanoma xenografts were established in athymic nude mice. Tumors were injected directly with HE7tk vector alone, HE7tk vector followed by ganciclovir ( GCV ), or a pHE700 amplicon vector carrying a green fluorescent protein ( HE7GFP ) gene followed by GCV. Efficient HSVtk transgene expression was found in the tumor 3 days after injection. Animals transduced with HE7tk followed by GCV had minimal tumor growth ( P < .01 ). Animals that received either HE7tk vector without GCV or HE7GFP vector with GCV had some reduction in tumor growth compared to animals that were injected with buffer only. These data indicate that replication -defective HSV -1 amplicon vectors can be used effectively to deliver transgenes into solid tumors in vivo.
H
erpes simplex virus type -1 ( HSV-1 ) vectors can efficiently transfer genes in vivo. 1 -7 Several groups are developing HSV-1 vectors as anticancer therapeutics. One of two broad categories of HSV-1 -based vectors is amplicons. 8 Plasmids with HSV-1 lytic replication origins ( ori S) and HSV-1 terminal packaging signal sequences can be amplified and packaged into infectious HSV-1 virions in the presence of helper virus. 8 -10 This plasmid system permits easier cloning and carries genomic information between prokaryotic and eukaryotic cells as a shuttle vector. 11 The amplicon systems retain the merits of HSV-1 vectors including high efficiency of gene transfer in vitro and in vivo, wide range of host, and neurotropism, but viral stocks tend to have lower titers and production is timeconsuming. 8,11 -14 We therefore created a new amplicon vector, pHE, that contains, in addition to HSV-1 origin and packaging sequences, an Epstein-Barr virus (EBV ) unique latent replication origin ( ori P ) and the EBV nuclear antigen 1 (EBNA -1 ). 15, 16 Investigators have previously demonstrated that plasmid vectors containing the EBV ori P that also expressed the EBNA -1 gene were more effective eukaryotic expression vectors and maintained the plasmid as an episome in the transfected cell nucleus. 17, 18 Various groups have used such EBNA -1 -based vectors for expression in human tumors with therapeutic intent. 19 The combination of the HSV-1 amplicon with EBV sequences improves the ease of use of the HSV-1 amplicon system. 15, 16 The new system overcomes the inconvenience of serial passaging to produce high -titer amplicon vector.
The addition of ganciclovir (GCV ) treatment to defective HSV-1 containing an intact HSVtk gene greatly enhances tumor killing. 20 The HSVtk gene is a negative selectable marker or ''suicide'' gene. HSVtk sensitizes the transduced tumor cells to GCV, an antiviral drug. 21 -23 GCV is phosphorylated by HSVtk, resulting in a monophosphate that cellular kinases convert to GCV -triphosphate, which inhibits DNA replication and causes cell death. An interesting in vitro and in vivo observation is that only a portion of tumor cells expressing HSVtk gene will induce complete tumor destruction. 21 This metabolic cooperation is a form of ''bystander effect'' and is due in large part to the transfer of phosphorylated GCV between cells through gap junctions. 21,24 -32 This gene transfer was then expected to sensitize solid tumors to GCV. Furthermore, a bystander effect caused by metabolic cooperation was to enhance the effect, so that if only a small portion of the tumor was transduced with HSVtk, then the entire tumor could be destroyed. In cell culture and animal models of HSVtk and GCV therapy, 10-20% of the tumor was needed to express the HSVtk gene to obtain complete response. 24,33 -37 In our current study, we evaluated the efficacy of direct injections of HE7tk amplicon vector into human melanoma xenografts in athymic nude mice followed by GCV treatment.
Materials and methods

Cell culture
The A375 human melanoma cell line was obtained from American Type Culture Collection (Rockville, MD ). E5 cells were derived from African green monkey kidney cells and these cells express the replication -permissive HSV-1 IE3 gene (kindly provided by N. DeLucca, University of Pittsburgh ). All cells were grown in Dulbecco's modified Eagle's medium ( DMEM; GibcoBRL, Gaithersburg, MD ) containing 10% fetal bovine serum (FBS ), 100 U of penicillin, 100 g of streptomycin, and 2 mM glutamine ( GibcoBRL ).
HE7tk and HE7GFP herpes amplicon vectors cloning and production
The pHE700 is a 10,617 -bp plasmid generated from the combination of components from several different plasmids. 15 The 1192-bp PCR product containing HSV-1 thymidine kinase (HSVtk ) open reading frame sequences was inserted into a HindIII site of the multicloning site of pHE700 under control of the cytomegalovirus (CMV ) immediate early promoter (Fig 1) . A DNA fragment containing a humanized, red shifted GFP marker gene under the control of the CMV promoter (pGFP; Clontech, Palo Alto, CA ) was inserted into the multicloning site of pHE700 to create HE7GFP. The HE7tk or HE7GFP plasmid was transfected into E5 cells with Lipofectamine per the manufacturer's protocol (GibcoBRL ) and placed under selection with hygromycin B (ICN Biomedical, Aurora, OH ) 1 day after transfection. By days 14 -16 of drug selection, hygromycin -resistant colonies were then trypsinized and 3Â10 6 cells plated on a 100-mm dish. To generate viral stocks, nearly confluent, selected E5 cells were infected with 0.01-0.1 multiplicity of infection (MOI ) of CgalÁ3 helper virus 38 (IE3 gene defective helper virus, kindly provided by P Johnson, University of California, San Diego). Two hours later, the virus solutions were removed and 10 mL of DMEM with 10% FBS was added and then incubated for an additional 24 -36 hours. The resulting supernatants contain both the HE7tk or HE7GFP amplicon vector and helper virus ( Fig 2 ) . 
In vitro
In vivo transgene expression study
To evaluate HSVtk gene and GFP expression, histology assays were performed on subcutaneous tumors injected in vivo. tfu ). For group 3, each tumor was injected with 100 L of HBSS. On days 3, 7, and 14 after intratumor injection, four mice were euthanized in a CO 2 chamber separately in each group. The mice from groups 1 and 3 were perfused transcardially with 20 mL of saline (378C ), followed by 60 mL of fixative containing 4% paraformaldehyde in 1Â PBS (pH 7.2 ) at 48C. Tumor samples were collected immediately and postfixed with the same fixative overnight at 48C, and then immersed in a 30% sucrose solution in 1Â PBS at 48C prior to cryosectioning. Tumor samples in group 2 were collected without fixation and kept at À 208C. After serial cryostat sectioning, two sets of frozen sections (20 -30 m thick) from fixed tumor samples were taken, one sample was processed for LacZ assay, and another for HSVtk immunohistochemistry. Frozen sections from unfixed tumor samples were visualized directly for GFP expression under a Nikon fluorescent microscope. 
Immunoperoxidase histochemistry
To detect expression of the HSVtk gene, one set of sections from fixed tumor samples was washed with 1Â PBS three times and incubated in anti -HSVtk primary antibody solution (1:400; Animal Pharm Services, Healdsburg, CA ) containing 0.3% Triton X -100 and 10% normal goat serum in 0.5Â PBS at 378C for 2 hours and then at 48C for 36-48 hours. The second incubation was performed in goat antirabbit secondary antibody conjugated with alkaline phosphatase solution ( 1:200; Sigma, St. Louis, MO ) containing 0.3% Triton X -100 and 10% normal goat serum in 0.5Â PBS at 378C for 2 hours. The third incubation was done in BCIP / NBT substrate solution ( Sigma) at room temperature for 5 -10 minutes. Several washes with 1Â PBS were done at the intervals between and after incubations. Part of the sections was evaluated further with -galactosidase histochemistry ( see below ) to determine if there was consistent distribution between HSVtk -immunoreactivepositive cells and -galactosidase -positive cells. The rest of the sections were dried, dehydrated, cleared, and coverslipped with Cytoseal 60 Mounting Medium ( Stephens Scientific, Riverdale, NJ ).
LacZ assay by X -gal staining
To detect -galactosidase produced from the LacZ reporter gene in CgalÁ3 helper virus, another set of sections from fixed tumor samples was incubated at 378C with 5 -bromo-4 -chloro-3-indolyl -D -galactoside (X -gal ) for 1 hour. Part of the sections was counterstained with Nuclear Fast Red ( Zymed, South San Francisco, CA ).
In vivo tumor growth inhibition study
To observe whether there is an enhancement of antitumor effect of GCV after HSVtk gene delivery in vivo, a xenograft tumor model in athymic nude mice was used. The tumors were generated as described above and two identical experiments were employed. For each experiment, 40 mice were subcutaneously injected with A375 cells in HBSS. After the tumor reaches 3-4 mm in diameter, 32 mice were placed in four groups ( eight mice per group ). In group 1 ( HSVtk + GCV group ) and group 2 ( HSVtk group ), each tumor was injected with 100 L of HE7tk supernatant (3Â10 6 tfu ). In group 3 ( GFP + GCV group ), each tumor was injected with 100 L of pHE700 -GFP supernatant (1Â10 6 tfu ). In group 4 (HBSS group, a control group ), no One day later, cells were fixed, incubated, and stained with anti -HSVtk antibody followed by alkaline phosphatase -conjugated secondary antibody ( Â100 magnification ).
Cancer Gene Therapy viral vectors were injected. Two days after the injection of the supernatant, mice from groups 1 and 3 were administered GCV by intraperitoneal injection for 10 days ( 1 mL per injection, 3 mg GCV /mL, twice daily ). For group 4, each mouse was given an intraperitoneal injection of 1 mL of HBSS, twice daily for 10 days. From 1 day before until 4 days after GCVadministration, tumor growth was monitored daily, and tumor size (in mm 3 ) was measured and calculated every 2 days. One -way ANOVA test was used for statistical comparisons of tumor volumes between different groups.
Results
Transduction and expression of the HE7tk amplicon vector in vitro
The HE7tk viral supernates were used to transduce human A375 melanoma cells in vitro. All cells were fixed and stained with anti -HSVtk primary antibody followed by a secondary antibody with alkaline phosphatase 1 day after infection. Positive HSVtk -immunoreactive cells were observed in HS7Vtk -transduced A375 cells (Fig 3) and in positive control cells (data not shown ). The percentage of positive cells decreased proportionately with greater dilutions of HE7tk supernatant used. No HSVtk -positive staining cells were found in HBSS -treated A375 cells ( negative control, data not shown ).
Expression of the HE7tk amplicon vector in human A375 melanoma xenografts
Three days after intratumoral injection of HE7tk supernate, many HSVtk -immunoreactive positive cells were found ( Fig 4A ) in each section of HE7tk -transduced tumor samples with anti -HSVtk antibody (primary, 1:400 ). No HSVtk -positive cells were found in the HBSS control group ( Fig 4B ) . A consistent distribution of HSVtkpositive cells and -gal -positive cells was found, and a few double -labeled cells were observed ( Fig 5 ) . Seven days after intratumoral injection, fewer HSVtk -positive cells or -gal -positive cells were found within tumors ( data not shown ). Fourteen days after intratumoral injection, only rare HSVtk -positive cells and -galpositive cells were found within tumors.
In vivo treatment of human A375 melanoma xenografts with HE7tk amplicon vector and GCV
The effects of HE7tk amplicon transduction plus GCV administration on subcutaneous tumor growth were evaluated by the serial measurement of tumor volumes of all experimental mice. Tumor volumes increased much faster in the HBSS control group than the treatment group ( HE7tk + GCV ) groups ( P <.001) (Fig 6 ) . Tumors of HE7tk amplicon vector + GCV group had significantly reduced growth compared to HE7GFP + GCV group (P < .02). No significant difference of increased tumor volume between HE7tk ( virus only ) group and HE7GFP + GCV group was found ( P> .05 ).
Discussion
The fundamental problem in trying to develop an effective cancer therapeutic is gene delivery. Previous clinical trials of glioblastoma patients by intratumoral implantation of a retroviral vector expressing HSVtk cells resulted in only low levels in vivo gene transfer into tumors. 40, 41 Several groups are working intensively to develop HSV-1 vectors as anticancer therapeutics because these vectors effectively transfer genes into tumors in vivo.
1 -5,42 -44 HSV-1 vectors also allow for high -efficiency gene transfer in vivo into rodent tumors. 20,45 -47 The HSV-1 amplicon containing a HSV-1 lytic replication origin ( ori S) and HSV-1 terminal 6 tfu of HE7tk amplicon vector ( Â200 ), or ( B ) the tumor was injected with HBSS alone ( negative control ) ( Â40 ). Three days after vector injection, the tumor tissues were fixed, sectioned, and stained with anti -HSVtk antibody ( primary, 1:400 ) followed by staining with alkaline phosphatase -conjugated antibody.
Cancer Gene Therapy packaging signal sequences can be amplified and packaged into infectious HSV-1 virions in the presence of transacting helper virus. 8, 9, 48, 49 We have constructed HSV-1 amplicons that also contain EBV sequences to maintain the plasmid as an episome in the transfected cell nucleus. 15, 16 EBV has been demonstrated to contain a unique latent replication origin ( ori P ), which directs viral self -replication and maintenance in cells without entering the lytic cycle. 17, 18 The EBV nuclear antigen 1 (EBNA -1 ) encodes a DNA binding transactivator for ori P. 17, 18, 50, 51 This replication -incompetent pHE vector maintained wide tropism for delivering transgene( s ) into both dividing and quiescent cells with high efficiency both in vitro and in vivo. 15, 16 The combination of the HSV-1 amplicon with the EBV sequences improves the ease of use of the system (Fig 2 ) . In the presence of helper virus, the amplicon replicates until a viral DNA 152 kb long is obtained and then packaged. Thus, for the HE7tk plasmid of approximately 11.5 kb, at least 13 expression cassettes will be present as tandem repeats in the resulting viral vector. Multiple copies of the transgene hopefully will improve transgene expression. The pHE vector could be produced at high titer and could package and carry a vector with a 21-kb DNA insert. 15 We have found that an MOI of 3-10 plaque -forming units ( pfu /mL ) transduces > 95% of tumor cells in vitro. 15 This compares favorably with higher MOI often required for adenoviral vectors (up to 3000 MOI in vitro ). 52 In the current study, packaged HE7tk supernates efficiently transduced human A375 melanoma cells using 0.1 -1 MOI of amplicon vector and high -level transgene expression was observed using anti -HSVtk antibody staining (Fig 3) .
Many tumor gene therapy models have explored using HSVtk as a suicide gene. Expression of HSVtk gene in tumor cells leads to cellular apoptosis when the cells are exposed to the antiviral prodrug, GCV. The HSVtk protein phosphorylates the GCV from prodrug into a toxic nucleotide analogue and in turn terminates DNA doublestrand elongation during DNA replication. A significant aspect of the HSVtk and GCV in combination is an in vitro bystander effect. 21, 24, 26, 30, 32, 53, 54 The transduction of a small fraction of the targeted cells may result in greaterthan -expected overall tumor killing effect. It has been shown that phosphorylated forms of GCV can travel from HSVtk -transduced cells to neighboring nontransduced cells via cellular gap junctions formed by connexins. 55 These bystander effects have also been observed in vivo. In our in vivo experiments, the volume of transplanted tumors in HBSS group increased much faster than other groups ( P <.01 ) ( Fig 6 ) . In contrast, tumors of TK + GCV group had significantly reduced tumor growth compared to the GFP + GCV group and TK group without GCV administration (P < .01 ) (Fig 6 ) . The CgalÁ3 helper virus is replication -defective due to the IE3 gene deletion. HSVtk gene expression in the helper virus depends upon expression of HSV-1 early genes and viral genome replication. The endogenous HSVtk gene, therefore, is expressed at minimal levels. HE7tk amplicon delivered HSVtk, resulting in much greater tumor suppression than that observed with GFP amplicon packaged with helper virus with GCV treatment. The difference of tumor growth inhibition between TK + GCV group and the other three groups appeared as early as 3 days after GCV injection ( P <.01 ). Of note, the difference between the HBSS group and GFP +GCV group and TK group was also significant ( P <.01 ). This likely reflects cytotoxicity of the helper virus on transduced cells. 6, 38, 56 GCV prodrug caused cytotoxicity in vitro, but this nonspecific cytotoxicity seemed minimized in vivo without HSVtk gene function, because no significant difference of tumor volume was seen between the TK group and GFP + GCV group ( P >.05 ). The cytotoxicity from helper virus may be beneficial as an additional killing effect against the tumor. Several groups have now designed helper free amplicon systems to address cytotoxicity. 57, 58 However, for antitumor applications, these systems may not necessarily be desirable because tumor cell killing is the goal of therapy.
Direct intratumoral injection is a simple and practical vector delivery method. The evaluation of gene transfer, expression, and distribution in tumor tissue after intratumoral 6 tfu of HE7tk amplicon vector was injected. Three days after vector injection, the tumor tissues were fixed, sectioned, and stained with anti -HSVtk antibody ( primary, 1:400 ) followed by staining with alkaline phosphatase -conjugated antibody ( dark color ). This was followed by incubation with X -gal solution to demonstrate -galactosidase activity ( blue ) ( Â200 magnification ).
Cancer Gene Therapy injection was performed by immunohistochemical staining of transduced tissue sections. Evidence of gene transfer and expression in vivo was demonstrated 3 days after HE7tk viral vector injection (Fig 4) . Consistent expression of TKimmunoreactive positive cells and -gal -positive cells was found in double -labeled tumor sections (Figs 4 and 5 ) . Several tumor cells showed a double -labeled TK and -gal staining in the same cell, indicating that at least two viral particles had transduced the cell (Fig 5 ) . As expected, no TK -or -gal -positive cells were found in the HBSS control group. Seven days after HE7tk vector injection, fewer TKpositive cells and -gal -positive cells were found compared to 3 days after injection. Only rare TK -and -gal -positive cells were found 14 days after intratumor injection. The transgene activity declined even when no GCV was administered. The loss of positive cells likely reflects a loss of virus from the tumor or a decrease in CMV promoter activity due to promoter methylation. Other promoter constructs might overcome this limitation. However, the maximal expression seen at 3 days may be sufficient to allow GCV activation. Immunological effects against the transgene or helper virus are also a possible explanation since athymic nude ( nu/ nu) mice retain NK cell function. Apparent limitations of gene expression may be more problematic.
Alternative amplicon systems are under development, which can generate helper virus free amplicon vectors. 44,57 -59 In addition, another new hybrid HSV /AAV amplicon vector system was created that may allow long -term transgene expression in brain and liver helper virus. 43, 60, 61 Finally, replication-competent herpes vectors under development may prove superior to replicationincompetent systems like ours. 62 The cytopathic replication -competent effects of modified HSV-1 viruses and their derived vectors can be used to excellent advantage against tumor cells. Martuza et al 63 first used thymidine kinase ( HSVtk ) -negative HSV-1 to treat human gliomas in nude mice. Mice treated with only 10 5 pfu of this defective virus had prolonged survival. The initial modified HSV-1 vectors were replication-competent. Because of concerns about infection (especially viral encephalitis ), other groups developed HSV-1 vectors defective in other genes such as ribonucleotide reductase, transcription factors ICP4 or ICP0, and 34.5 gene. 20, 45, 64, 65 Recently, efforts have focused on HSV-1 mutants with multiple specific gene deletions to enhance their therapeutic index. 6,66 -68 Further experiments are planned with our system to focus on multiple gene combinations and selective promoters to achieve high -level, localized gene expression. In conclusion, the HE7tk amplicon viral vector can efficiently transduce A375 tumor cells in vitro and solid tumors in vivo. After GCV administration, significant tumor growth suppression can be observed. Figure 6 Treatment of A375 melanoma xenograft implanted into athymic nude mice. Animals were divided into four groups, each with 16 mice, after subcutaneous injection of 5Â10 6 A375 human melanoma cells. When the tumor reached approximately 4 mm in diameter, two groups of animals were injected directly into the tumor masses with HE7tk amplicon vector. Two other groups were injected with either HE7GFP amplicon vector or HBSS, respectively. One group of animals injected with HE7tk and the group injected with HE7GFP were then administered GCV ( 6 mg / day ) for 10 days starting on day 2 after viral vectors injection. The mean tumor volumes were measured and plotted. Animals that received mock injection with HBSS had the most rapid tumor growth. Animals that received injections of HE7tk virus alone or HE7GFP vector followed by GCV had some decrease in tumor growth. Animals that received HE7tk amplicon vector and GCV had the greatest reduction in tumor growth rate. All tumor volume values plotted are mean ± SE.
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